RMTI logo

Rockwell Medical, Inc. Stock Price

NasdaqCM:RMTI Community·US$39.8m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 13 Fair Values set on narratives written by author

RMTI Share Price Performance

US$1.01
-0.89 (-46.84%)
US$5.00
Fair Value
US$1.01
-0.89 (-46.84%)
79.8% undervalued intrinsic discount
US$5.00
Fair Value
Price US$1.01
AnalystHighTarget US$5.00
AnalystLowTarget US$2.50
AnalystConsensusTarget US$4.00

RMTI Community Narratives

AnalystHighTarget·
Fair Value US$5 79.8% undervalued intrinsic discount

Aging And Home Care Trends Will Raise Demand Amid Risks

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystLowTarget·
Fair Value US$2.5 59.6% undervalued intrinsic discount

Dialysis Loss Will Squeeze Margins Yet Yield Cautious Relief

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·
Fair Value US$4 74.8% undervalued intrinsic discount

Dialysis Demand Will Grow Despite Margin And Market Challenges

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
US$5
79.8% undervalued intrinsic discount
Revenue
-6.77% p.a.
Profit Margin
12.32%
Future PE
29.31x
Price in 2028
US$6.18

Trending Discussion

Updated Narratives

RMTI logo

RMTI: Diversified Revenue And Extended Contracts Will Support Future Repricing

Fair Value: US$2.5 59.6% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RMTI logo

Aging And Home Care Trends Will Raise Demand Amid Risks

Fair Value: US$5 79.8% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RMTI logo

Dialysis Demand Will Grow Despite Margin And Market Challenges

Fair Value: US$4 74.8% undervalued intrinsic discount
7 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
0 Rewards

Rockwell Medical, Inc. Key Details

US$75.6m

Revenue

US$64.1m

Cost of Revenue

US$11.4m

Gross Profit

US$17.4m

Other Expenses

-US$5.9m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.15
15.15%
-7.85%
24.8%
View Full Analysis

About RMTI

Founded
1996
Employees
244
CEO
Mark Strobeck
WebsiteView website
www.rockwellmed.com

Rockwell Medical, Inc., together with its subsidiaries, develops, manufactures, commercializes, and distributes various hemodialysis products for dialysis providers worldwide. The company offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, centrisol and renasol hemodialysis concentrates, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. Its hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. In addition, the company offers dialysis concentrates, dialysis kits, and other ancillary products used in the dialysis process. The company was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Recent RMTI News & Updates

Recent updates

No updates